Caladrius Biosciences - 48 Year Dividend History | CLBS

Historical dividend payout and yield for Caladrius Biosciences (CLBS) since 1971. The current TTM dividend payout for Caladrius Biosciences (CLBS) as of June 19, 2019 is $0.00. The current dividend yield for Caladrius Biosciences as of June 19, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.030B $0.035B
Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $110.770B 12.52
Gilead Sciences (GILD) United States $86.948B 10.56
Bio-Techne Corp (TECH) United States $7.858B 53.62